Stocks · US
SOLV
XNYS
Solventum Corporation
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E10.45x
P/B3.12x
P/S1.80x
EPS$8.42
ROE29.88%
ROA10.07%
Dividend yield0.00%
EV/EBITDA19.23x
Debt/Equity1.10
Free cash flow$-118M
Returns and 52-week range
1W-2.55%
1M-5.07%
3M+15.78%
6M+39.29%
1Y+17.62%
YTD+10.15%
52W high$94.16
52W low$62.38
From 52W high-7.56%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| 템퍼스 AI | $15.2B | — | 34.09 | +11.39% |
| Charles River Laboratories International, Inc. | $14.8B | — | 5.22 | +5.71% |
| Jazz Pharmaceuticals, Inc. | $15.3B | 16.29 | 3.19 | -6.25% |
| Neurocrine Biosciences Inc | $14.7B | 20.78 | 3.97 | -6.51% |
| Medpace Holdings, Inc. Common Stock | $17.3B | 35.24 | 39.92 | +1.96% |
| Exelixis Inc | $14.6B | 16.94 | 7.91 | -1.15% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.